Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension.
Respir Med Case Rep
; 37: 101646, 2022.
Article
in English
| MEDLINE | ID: covidwho-1799736
ABSTRACT
There are no prospective studies or guidelines describing transition between selexipag and oral treprostinil. We present two different transition strategies from selexipag to oral treprostinil, one started inpatient and then completed at home, and one completely under outpatient settings. Neither patient experienced worsening prostacyclin-type adverse effects; both were rigorous in their attention to a 7-8 hour administration schedule for oral treprostinil, and both experienced objective clinical benefit at follow-up. Prospective studies are needed to help guide clinical decisions when patients remain intermediate risk after a trial of either drug.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Respir Med Case Rep
Year:
2022
Document Type:
Article
Affiliation country:
J.rmcr.2022.101646
Similar
MEDLINE
...
LILACS
LIS